Last reviewed · How we verify
LY010616
At a glance
| Generic name | LY010616 |
|---|---|
| Also known as | Irinotecan Hydrochloride and Floxuridine liposome Injection |
| Sponsor | Luye Pharma Group Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety, Tolerability, Pharmacokinetics (PK), and Primary Clinical Efficacy of LY01616 in Patients With Advanced Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LY010616 CI brief — competitive landscape report
- LY010616 updates RSS · CI watch RSS
- Luye Pharma Group Ltd. portfolio CI